Last reviewed · How we verify
NTB003
At a glance
| Generic name | NTB003 |
|---|---|
| Sponsor | Nanjing Chia-tai Tianqing Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) (PHASE1, PHASE2)
- Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NTB003 CI brief — competitive landscape report
- NTB003 updates RSS · CI watch RSS
- Nanjing Chia-tai Tianqing Pharmaceutical portfolio CI